ReviewStem cell research & therapy2025
Mesenchymal stem cell-derived exosomes as cell-free therapeutics: mechanistic insights and engineering strategies for liver disease treatment.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Human Umbilical Cord Mesenchymal Stem Cells in Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) Therapy: Mechanisms, Clinical Efficacy, and Future Perspectives.Stem cell reviews and reports · 2026Review
- Exosomes target liver TREM-1 to break the systemic inflammatory cascade and improve spinal cord injury outcomes.Journal of orthopaedic translation · 2026Article
- Review
- Injectable bioactive hydrogels as pharmacological drug delivery platforms for post-myocardial infarction cardiac repair: therapeutic cargo engineering, stimuli-responsive release mechanisms, and translational perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Cell therapy comparison of dental pulp stem cells, hepatocytes, and their exosomes for liver fibrosis treatment in rats.Animal models and experimental medicine · 2026Article
- Mannose receptor-targeted MSC-derived exosomes as a high-affinity delivery platform for liver sinusoidal endothelial cells.Drug delivery and translational research · 2026Article
- Regenerative Therapy at the Crossroads: From Cell-Based to Cell-Free Precision Medicine.Bioengineering (Basel, Switzerland) · 2026Article
- Canine Adipose MSC-Derived Exosomes Ameliorate Skeletal Muscle Injury in Mice.Animals : an open access journal from MDPI · 2026Article
- Harnessing MSCs plasticity: mechanisms and determinants of bidirectional immune regulation in stem-cell-based immunotherapy.Stem cell research & therapy · 2026Review
- Cell Therapy in Advanced Cirrhosis: From Preclinical Evidence to Clinical Application.Gastro hep advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver diseases pose a global health crisis, with liver transplantation remaining the only definitive therapy yet constrained by donor scarcity and complications. Mesenchymal stem cells (MSCs), emerging as stromal cells with immunomodulatory and regenerative capacities, face translational challenges. By contrast, MSC-derived exosomes (MSC-Exos) offer a cell-free approach with lower immunogenicity, minimal tumorigenic risk, and intrinsic hepatic tropism, mediating intercellular communication via protein and microRNA (miRNAs) cargo. To provide a focused synthesis, this review establishes a unified four-pillar framework of MSC-Exos mechanisms across liver pathologies, including (i) maintaining immunological-stromal homeostasis, (ii) reprogramming metabolic circuitry, (iii) determining cell fate, and (iv) intercepting oncogenic signaling. We further discuss advances in engineered MSC-Exos from preparation and application, aiming at enabling precision delivery and the mechanism-to-translation process. While MSC-Exos represent a transformative frontier in hepatology, addressing heterogeneity, scalable production, and cargo standardization remains critical to accelerate clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.